Overview

Hyperpolarized Imaging in Diagnosing Participants With Glioma

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
Phase:
Phase 1
Details
Lead Sponsor:
Susan Chang
Collaborator:
National Cancer Institute (NCI)
Treatments:
Temozolomide